⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17238898 | 1.00 | — | — | |
| SCHEMBL17238890 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28784199 | 0.97 | DPP4 (0.32) | — | |
| SCHEMBL2540586 | 0.83 | ATR (0.31) | — | |
| SCHEMBL2536776 | 0.81 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL7044962 | 0.81 | — | — | |
| SCHEMBL23387874 | 0.79 | LMNA (0.36) | — | |
| SCHEMBL2537167 | 0.79 | LMNA (0.36) | — | |
| SCHEMBL2541297 | 0.79 | LMNA (0.36) | — | |
| SCHEMBL23140231 | 0.76 | THRB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | claimed |
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3873467-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-11970479-B2 | 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-3183255-B1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3183255-B1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |